Plain-English translation of NCT05928728 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a medication commonly used to treat gout and inflammation, can help prevent atrial fibrillation (irregular heartbeat) from returning in patients whose heart rhythm has just been successfully restored. About 500 people will take either the medication or a placebo (a dummy pill) for one year to see if reduces the chances of the irregular heartbeat coming back.
Atrial fibrillation often returns even after successful treatment, and there is a need for better ways to prevent this recurrence. This trial is exploring whether this medication's anti-inflammatory properties might help keep the heart rhythm stable over the long term.
You likely qualify if…
You likely don't qualify if…
You will visit the hospital at the start of the study and then again at 6 months and 12 months. At each visit, you will have heart tests including an ECG (electrical heart recording), an ultrasound of your heart, possibly an MRI scan, and blood work. Every day for 12 months, you will take one pill—either the medication or a placebo—and keep track of how you feel. The research team will monitor when and if your irregular heartbeat returns and compare outcomes between those taking the medication and those taking the placebo.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Denmark
Phase
Large-scale testing
Sponsor
Herlev and Gentofte Hospital
Enrollment target
~500 participants
Started
July 2023
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Adam Femerling Langhoff, M.D.
Herlev and Gentofte Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.